Literature DB >> 23719840

Microfilaments make mast cells migrate (rather than degranulate).

Michael Huber1.   

Abstract

Expression of the high-affinity receptor for IgE (FcεRI) provides mast cells with the ability to react in a proinflammatory manner to antigens (Ags). In particular, the immediate secretion of preformed mediators from secretory lysosomes (degranulation) is typical for FcεRI-mediated mast cell activation. In addition to the FcεRI, the stem cell factor receptor, KIT, is expressed at high levels on the surface of mast cells. KIT activation controls mast cell differentiation and survival in vivo and potently stimulates the chemotaxis of these cells. Although FcεRI and KIT initiate many of the same early signaling events in mast cells, FcεRI activation results in potent degranulation and a poor chemotactic response while KIT activation triggers very little degranulation and a strong chemotactic response. Novel data published in this issue of the European Journal of Immunology [Smrž et al. Eur. J. Immunol. 2013. 43: 1873-1882] demonstrate that actin de- and repolymerization, involved in both degranulation and chemotaxis, make all the difference: Pharmacological suppression of F-actin formation converts activated KIT into a strong degranulator. The possible implications for mast cell physiology and pathophysiology are discussed in this Commentary.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Allergology; Asthma; Cell migration; Cellular activation; Mast cells

Mesh:

Substances:

Year:  2013        PMID: 23719840     DOI: 10.1002/eji.201343706

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  1 in total

1.  Somatostatin inhibits the production of interferon-γ by intestinal epithelial cells during intestinal ischemia-reperfusion in macaques.

Authors:  Ling Liu; Qinghua Tan; Bin Hu; Hao Wu; Chunhui Wang; Chengwei Tang
Journal:  Dig Dis Sci       Date:  2014-05-06       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.